<!DOCTYPE html>
<html lang="en">
    <head>
		<title>ISI [slide-01]</title>
		<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
		<meta name="viewport" content="initial-scale = 1.0, user-scalable = no" />
		<meta name="apple-mobile-web-app-capable" content="YES" />
		<meta name="apple-mobile-web-app-status-bar-style" content="black" />
		<meta name="format-detection" content="telephone=no" />
		<link rel="stylesheet" href="css/fonts.css" type="text/css" />
		<link rel="stylesheet" href="css/animate.css" type="text/css" />
		<link rel="stylesheet" href="css/global.css" type="text/css" />
		<link rel="stylesheet" href="css/isi.css" type="text/css" />
		<script type="text/javascript" src="js/Common.js"></script>
		<script type="text/javascript" src="js/base.js"></script>
		<script type="text/javascript" charset="utf-8">
			
			var ANIMATION = [];
			
            </script>
    </head>
    <body class="indication slide-01">
        <div id="container">
            <header>Indication and Safety Information</header>
            <section>
                <h2>Indication<sup>1</sup></h2>
                <p>SYNTHROID<sup>Â®</sup> (levothyroxine sodium tablets, USP) is indicated as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter.
                </p>
                <br>
                <h2>Safety Considerations</h2>
                <p><strong>SYNTHROID should not be used for the treatment of obesity or for weight loss.</strong> SYNTHROID is contraindicated in the following: patients with untreated subclinical or overt thyrotoxicosis, acute myocardial infarction, uncorrected adrenal insufficiency, and hypersensitivity to inactive tablet <br>ingredients. SYNTHROID is contraindicated in patients with nontoxic diffuse goiter or nodular thyroid disease, if the serum TSH level is already <br>suppressed. If TSH is not suppressed, use in conjunction with careful clinical and TSH monitoring. SYNTHROID is a narrow therapeutic index drug requiring careful titration. </p>  
                <br>
                <!--
                 <p><strong>Reference:</strong> 1. Synthroid [package insert]. North Chicago, IL: Abbott Laboratories.</p>
                 -->
            </section>
            <footer> <span>Please tap above for Important Safety Information,<br> including
                BOXED WARNING regarding inappropriate<br>treatment for obesity.</span> 
                <div id="breadcrumb">
                Clinical Consequences&nbsp;
					<div class="bullets"><img src="images/global-dot-active.png" height="9" width="10"></div>
			    	<div class="bullets"><img src="images/global-dot.png" height="9" width="10"></div>
			    	<div class="bullets"><img src="images/global-dot.png" height="9" width="10"></div>
			    	<div class="bullets"><img src="images/global-dot.png" height="9" width="10"></div>
			</div>
                
                <div class="logo"><img src="images/footer-logo2.png" width="257" height="75" alt="" /></div></footer>
        </div>
        <!-- END #container -->
        
    </body>
    
</html>